Kevin Charles Gorman - 13 Feb 2024 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role: Chief Executive Officer, Director
Signature: /s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol: NBIX
Transactions as of: 13 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 14 Feb 2024, 17:17:01 UTC
Previous filing: 08 Feb 2024
Next filing: 17 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NBIX	Common Stock	Options Exercise	$99,980	+2,778	+0.55%	$35.99	509,740	13 Feb 2024	Direct	F1
transaction	NBIX	Common Stock	Options Exercise	$99,971	+2,312	+0.45%	$43.24	512,052	13 Feb 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NBIX	Incentive Stock Option	Options Exercise	$99,980	-2,778	-100%	$35.99	0	13 Feb 2024	Common Stock	2,778	$35.99	Direct	F3
transaction	NBIX	Incentive Stock Option	Options Exercise	$99,971	-2,312	-100%	$43.24	0	13 Feb 2024	Common Stock	2,312	$43.24	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.
F2	491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.
F3	The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016.
F4	The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017.